Article

Lecia V. Sequist on Side Effects From Agents for Resistant Lung Cancer

Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).

Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291), two agents specific to acquired T790M mutations in EGFR-positive non-small cell lung cancer (NSCLC).

Related Videos
Image of man with black hair.
Image of a man with dark hair and some facial hair.
Image of a man with blond facial hair.
Image of woman with blonde hair.
Image of a woman with long red hair.
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short hair, wearing a buttoned-up shirt.
Image of a man with short black hair.
Related Content